[Form 4] DatChat, Inc. Series A Warrant Insider Trading Activity

Rhea-AI Filing Summary

Myseum, Inc. (MYSE) reported that director Peter Shelus was granted options to buy 25,000 shares of the company's common stock on 08/18/2025 under the Amended and Restated 2021 Equity Incentive Plan. The options have an exercise price of $3 per share, vest in four equal semiannual installments with the first vesting six months after issuance, and expire on 08/18/2030. Following the grant, the reporting person beneficially owns 25,000 options directly. The Form 4 was signed on 08/19/2025.

Positive

• Director alignment: Grant aligns the director's incentives with shareholder value through equity compensation
• Clear vesting schedule: Options vest in four equal semiannual installments, promoting retention over time

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: A standard equity grant to align a director with shareholder interests; not immediately dilutive until exercised.

This filing documents a non-derivative equity compensation grant to a director rather than a sale or disposition. The structure—25,000 options with a five-year term and semiannual vesting—appears designed to retain and incentivize ongoing board service. The exercise price of $3 establishes the threshold for future dilution only if and when exercised. For governance assessment, this is routine director compensation activity and does not indicate a change in control or liquidity event.

Securities Analyst

TL;DR: Material only as a disclosure of insider ownership change; unlikely to affect near-term valuation.

The Form 4 discloses a 25,000-option grant exercisable through 2030. Because these are options rather than issued shares, immediate share count and cash position are unaffected. The potential dilution equals 25,000 shares if fully exercised. Investors should note the exercise price and vesting schedule when modeling potential future dilution, but this single grant is small unless the company has a very low share base.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shelus Peter

(Last) (First) (Middle)

C/O MYSEUM, INC.

65 CHURCH STREET, SUITE 230

(Street)

NEW BRUNSWICK NJ 08901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Myseum, Inc. [ MYSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$3	08/18/2025		A		25,000		(1)	08/18/2030	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. On August 18, 2025, the Reporting Person was granted options ("Options") to purchase up to 25,000 shares of the Registrant's common stock pursuant to the Registrant's Amended and Restated 2021 Equity Incentive Plan. The Options will vest in four equal installments semiannually, with the first installment vesting six months from the date of issuance.

	/s/ Peter Shelus	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 and what was disclosed for MYSE?

The Form 4 was filed by director Peter Shelus, disclosing a grant of 25,000 options on 08/18/2025 to purchase common stock.

What are the key terms of the options granted to the reporting person?

The options have an exercise price of $3, vest in four equal semiannual installments starting six months after issuance, and expire on 08/18/2030.

Does this Form 4 report a sale of shares or an acquisition?

This Form 4 reports a grant of options (an acquisition of derivative securities), not a sale of existing shares.

How many shares would be added to the float if the options are exercised?

If fully exercised, the options would result in 25,000 additional common shares outstanding.

When was the Form 4 signed?

The filing includes the reporting person's signature dated 08/19/2025.